only approximately 20% of individuals with these mutations clinically manifest PPH, environmental (epigenetic) or other disease-modifying genes are likely to be important in disease pathogen&s. One such candidate disease-modifying gene could be 5lipoxygenase (5LO), whose expression is increased in patients with PPH. Methods: In this study, we examined the consequences of 5L0 overexpression in the lungs of mce heterozygous for the mutated BMPRP gene (+/-).
Results: BMPRZ (+/-) mice had normal pulmonary artery systolic pressures (10 * 2 mmHg, n=5), compared to wild type mice (11 + 2 mmlig. n=7). Delivery of a replicationdeficient adenovirus expressing 5L0 to the lungs of BMPRP (+/-) mice led to an increase in pulmonary artery systolic pressure (24 * 1 mmHg, n=7) by day 12. at which time wild type mice treated with the same adenoviral vector containing 5L0 maintained normal
pressures (13 f 4 mmHg, n=7). These data show that 5.LO modifies the susceptibility of BMPRP (+/-) mice to the development of PPH. Prior data usmg cultured endothelial and vascular smooth muscle cells showed that 5L0 expression and BMPRP haploinsuffciency both can promote vascular cell proliferation, and that 5L0 can induce endothelial and vascular dysfunction.
Conclusion:
Our data in mice together wth these earlier observations in cultured cells suggest a potential mechanism by which these molecular mediators suppolt the development of PPH by promoting vascular dysfunction and cell growth. This enzyme has been suggested to play a role in reducing NO-mediated resporises. However, the role of arginase in regulating NOS activity in the lung has not been addressed. The present study was designed to compare arginase expression, activity, and functional role in the pulmonary vascular bed of the mouse. Arginase mRNA, protein, and activity were significantly greater in mice exposed to 30 days of chronic hypoxia when compared to control mice. In contrast, while eNOS mRNA and protein were elevated in hypoxlc mice, eNOS activity was lower when compared to norm&c mwa. However, when assessed in the presence of ABH (a potent, selective inhibitor of arginase), NOS activity returned to levels similar to those observed in normoxic mice. In viva studies I" the pulmonary vascular bed of the intact-chest mouse revealed that chronic administration of ABH to hypoxic mice reduced the elevated pulmonary arterial pressure (PAP), pulmonary vascular resistance (PVR), and increase in RV free wall weight (RVFWW) associated with hypoxia. In contrast, in viva gene transfer of arginase, wng an adenoviral vector, resulted in higher PAP, PVR and increased RVFWW. When taken collectively, these data suggest that increased argmase expresslon plays a role in the exprasslon of pulmonary hypertension in chronic hypoxia. We hypothesize that arginase may function by depleting endothelial levels of L-arginine and thus reduce the NOS actvity thus the augmenting the hypoxic response in the mouse. and by cell number count and cell viability was evaluated by trypan blue exclusion method at baseline, 24, 46 and 72 hours. The experiments were repeated after the selective inhibition of protein kinase G (PKG) or A (PKA). Four sets of experiments were performed for each combination. Results: 50 or 100 nM sildenafil significantly reduced PASMC proliferation as assessed by both MTT metabolism and cell number count (Fig 1) . PASMC viability was not affected by sildenafil. The antiproliferative effect of sildenafil was blupted only in part by the selective inhibition of PKG or PKA (27+3 x lo4 vs 44i6 x IO4 or 44-6 x l@ cell numher. p < 0.004 by ANOVA).
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Conclusions:
Sildenafil exerts a potent antiproliferatwe effect on PASMC stimulated by PDGF. This effect is mediated via both cGMP and CAMP dependent pathways.
